Pharmacologic management of types 1 and 2 diabetes mellitus and their complications in women of childbearing age

Pharmacotherapy

Volumn 35, Issue 2, 2015, Pages 158-174

  Mukherjee, Mimi S ^a   Coppenrath, Valerie A ^a   Dallinga, Bree A ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Edward M Kennedy Community Health Center   (United States)

Author keywords

congenital malformation; contraception; diabetes; hypertension; lipids; metabolic syndrome; pregnancy; teratogen; women's health

Indexed keywords

ACARBOSE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROPAMIDE; COLESEVELAM; CONTRACEPTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EXENDIN 4; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MEVINOLIN; NIFEDIPINE; PIG INSULIN; PRAMLINTIDE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; VERAPAMIL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONGENITAL DISORDER; CONTRACEPTION; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSLIPIDEMIA; EMERGENCY CONTRACEPTION; FEMALE; FETUS OUTCOME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTRAUTERINE CONTRACEPTIVE DEVICE; MATERNAL HYPERTENSION; MOLECULAR WEIGHT; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SPONTANEOUS ABORTION; SYSTOLIC BLOOD PRESSURE; TERATOGENICITY; TRANSDERMAL PATCH; UNPLANNED PREGNANCY; WEIGHT GAIN; ANIMAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; PROCEDURES;

ANIMALS; BLOOD GLUCOSE; CONTRACEPTION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME;

EID: 84923451196     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1535     Document Type: Review

References (82)

1. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care 2008; 31: 1060-79.
2. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinic practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17 (Suppl 2): 1-53.
3. Homko CJ, Jornsay D,. Pregnancy: preconception to postpartum. In:, Franz MJ, ed. A core curriculum for diabetes education: diabetes in the life cycle and research, 4th ed. Chicago, IL: American Association of Diabetes Educators, 2001: 33-72.
4. Rosenn B, Miodovinik M, Kranias G, et al. Progression of diabetic retinopathy in pregnancy: association with hypertension in pregnancy. Am J Obstet Gynecol 1992; 166: 1214-8.
5. Miller E, Hare JW, Cloherty JP, et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981; 304: 1331-4.
6. Pollex EK, Feig SA, Koren G,. Oral hypoglycemic therapy: understanding the mechanisms of transplacental transfer. J Matern Fetal Neonatal Med 2010; 23: 224-8.
7. Rogovskaya S, Rivera R, Grimes DA, Chen PL, Prilepskaya V, Kulakov V,. Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005; 105: 811-5.
8. Vicente L, Mendonca D, Dingle M, Duarte R, Boavida JM,. Etonogestrel implant in women with diabetes mellitus. Eur J Contracept Reprod Health Care 2008; 13: 387-95.
9. Peterson K, Skouby S, Jespersen J,. Contraception guidance in women with pre-existing disturbances in carbohydrate metabolism. Eur J Contracept Reprod Health Care 1996; 1: 53-9.
10. Gourdy P,. Diabetes and oral contraception. Best Pract Res Clin Endocrinol Metab 2013; 27: 67-76.
11. Janssen Pharmaceuticals. Micronor (norethindrone) package insert. Toronto, ON; 2012.
12. Vickery G, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF,. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013; 88: 503-8.
13. Verhaeghe J,. Hormonal contraception in women with the metabolic syndrome: a narrative review. Eur J Contracept Reprod Health Care 2010; 15: 305-13.
14. Merck. NEXPLANON (package insert). Whitehouse Station, NJ; 2013.
15. Bayer Pharmaceuticals. Mirena (package insert). Whippany, NJ; 2014.
16. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107: 1453-72.
17. Darney PD,. OC practice guidelines: minimizing side effects. Int J Fertil Womens Med 1997; 42 (Suppl 1): 158-69.
18. Pfizer. DEPO-subQ provera 104 (package insert). New York, NY; 2013.
19. Le YL, Rahman M, Berenson AB, Abbey B,. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol 2009; 114 (2 Pt 1): 279-84.
20. Abdikkahi M, Cushman M, Rosendaal F,. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-8.
21. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkgaard E,. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-2009. BMJ 2011; 343: 339-43.
22. Holt V, Scholes D, Wicklund KG, Cushing-Haugen KL, Daling J,. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 2005; 105: 46-52.
23. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AE, Creasy GW,. Contraceptive efficacy and cycle control with OrthoEvra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002; 77: S13-8.
24. Moreau C, Trussell J,. Results from pooled phase II studies of ulipristal acetate for emergency contraception. Contraception 2012; 86: 673-80.
25. Leiman G,. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am J Obstet Gynecol 1972; 114: 97-102.
26. Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011; 84: 363-7.
27. Dilbaz B, Ozdegirmenci O, Caliskan E, Dilbaz S, Haberal A,. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels. Contraception 2010; 81: 510-4.
28. Mohamed A, El-Sherbiny W, Mostafa W,. Combined contraceptive ring versus combined oral contraceptive (30-microgram ethinylestradiol and 3 mg drospirenone). Int J Gynaecol Obstet 2011; 114: 145-8.
29. Grigoryan O, Grodinitskaya EE, Andreeva EN, Shestakova MV, Melnichenko GA, Dedov II,. Contraception in perimenopausal women with diabetes mellitus. Gynecol Endocrinol 2006; 22: 198-206.
30. Visser J, Snel M, Van Vilet HA,. Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and type 2. Cochrane Database Syst Rev 2013; 3: CD003990.
31. Department of Reproductive Health, World Health Organization. Medical eligibility criteria for contraceptive use, 4th ed., 2009. Available from http://whqlibdoc.who.int/publications/2010/9789241563888eng.pdf. Accessed February 8, 2014.
32. Briggs GG, Freeman RK, Yaffe SJ,. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. Philadelphia, PA: Lippincott Williams and Wilkins, 2011.
33. Bhattacharyya A, Brown S, Hughes S, Vice PA,. Insulin lispro and regular insulin in pregnancy. QJM 2001; 94: 255.
34. Wyatt JW, Frias JL, Jovanovic L, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 2004; 46 (Suppl 2): 803-7.
35. Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007; 30: 771.
36. Hod M, Damm P, Risto K, et al. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 2008; 198: 186.e1-e7.
37. Singh C, Jovanovic L,. Insulin analogues in the treatment of diabetes in pregnancy. Obstet Gynecol Clin North Am 2007; 34: 275-91.
38. Mathiesen ER, Hod M, Ivanisevic M, et al. Maternal efficacy and safety outcomes in a randomized controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes mellitus. Diabetes Care 2012; 35: 2012-6.
39. Lepercq J, Lin J, Hall GC, et al. Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int 2012; 2012: 649070.
40. Agarwal MM, Punnose J,. Recent advances in the treatment of gestational diabetes. Expert Opin Investig Drugs 2004; 13: 1103-11.
41. Towner D, Siri LK, Leung B, et al. Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 1995; 18: 1446-50.
42. Elliot BD, Langer O, Schenker S, Johnson RF,. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991; 165: 807-12.
43. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O,. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134-8.
44. Elliott BD, Schenker S, Langer O, Johnson R, Prihoda T,. Comparative placental transport of oral hypoglycemic agents in humans: a model of human placental drug transfer. Am J Obstet Gynecol 1994; 171: 653-60.
45. Kalyoncu NI, Yaris F, Kadioglu M, et al. Pregnancy outcome following exposure to orlistat, ramilpril, glimepiride in a woman with metabolic syndrome. Saudi Med J 2005; 26: 497-9.
46. Rowan JA, Hague WM, Wanzhen G, Battin MR, Moore MP,. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003-15.
47. Bayer Healthcare Pharmaceuticals. Precose (acarbose) package insert. Wayne, NJ; 2011.
48. De Veciana M, Trail PA, Evans AT, Dulaney K,. A comparison of oral acarbose and insulin in women with gestational diabetes mellitus [abstract]. Obstet Gynecol 2002; 99 (Suppl): 5S.
49. Zárate A, Ochoa R, Hernández M, Basurto L,. Effectiveness of acarbose in the control of glucose tolerance worsening in pregnancy. Ginecol Obstet Mex 2000; 68: 42-5.
50. Haddad GF, Cristiano J, Thomas MA, Williams DB, Aubuchon M,. Case series of rosiglitazone used during the first trimester of pregnancy. Reprod Toxicol 2008; 26: 183-4.
51. Kalyoncu NI, Yaris F, Ulku C, et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005b; 19: 563-4.
52. Yaris F, Yrais E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI,. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004; 18: 619-21.
53. Boehringer Ingelheim. Tradjenta (linagliptin) package insert. Ridgefield, CT; 2013.
54. Takeda Pharmaceuticals. Nesina (alogliptin) package insert. Deerfield, IL; 2013.
55. Janssen Pharmaceuticals. Invokana (canagliflozin) package insert. Titusville, NJ; 2013.
56. Bristol-Myers Squibb. Farxiga (dapagliflozin) package insert. Princeton, NJ; 2014.
57. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ, Abalos E,. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Cochrane Review). The Cochrane Library 2010 Issue 1. Chichester: John Wiley and Sons, Ltd; 2010.
58. Friedman JM,. ACE inhibitors and congenital anomalies. N Engl J Med 2006; 354: 2498-500.
59. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, SImonette GD,. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60: 444-50.
60. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443-51.
61. Lennestal R, Otterblad OP, Kallen B,. Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol 2009; 65: 615-25.
62. Li D, Yang C, Andrade S, Tavares V, Ferber JR,. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. BMJ 2011; 343: d5931.
63. Diav-Citrin O, Shechtman S, Halberstadt Y, et al. Pregnancy outcome after in utero exposure to angiotensin converting enzyme inhibitors or angiotensin receptor blockers. Reprod Toxicol 2011; 31: 540-5.
64. Vasilakis-Scaramozza C, Aschengrau A, Cabral HJ, Jick SS,. Antihypertensive drugs and the risk of congenital anomalies. Pharmacotherapy 2013; 22: 476-82.
65. Magee LA, Schick B, Donnonfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol 1996; 174: 823-8.
66. Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol 2008; 26: 24-30.
67. Yakoob MY, Bateman BT, Ho E, et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy. Hypertension 2013; 62: 375-81.
68. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). 2014 Evidence-based guideline for the management of high blood pressure in adults. JAMA 2014; 311: 507-20.
69. Kidney disease: improving global outcomes (KDIGO) blood pressure work group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2012; 2 (Suppl 2): 337-414.
70. American Heart Association. Cardiovascular disease and diabetes. Available from: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes-UCM-313865-Article.jsp. Published July 5, 2012. Updated January 31, 2013. Accessed March 28, 2014.
71. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2014; 37: S14-80.
72. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 13: S0735-1097.
73. Patel C, Edgerton L,. What precautions should we use with statins for women of childbearing age? J Fam Pract 2006; 55: 75-7.
74. Pollack PS, Shields KE, Burnett DM, Osborne MJ, Cunningham ML, Stepanavage ME,. Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Res A Clin Mol Teratol 2005; 73: 888-96.
75. Eapen DJ, Valiani K, Reddy S, Sperling L,. Management of familial hypercholesterolemia during pregnancy: case series and discussion. J Clin Lipidol 2012; 6: 88-91.
76. Mooradian AD,. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5: 150-9.
77. Insull W,. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99: 257-73.
78. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL,. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007; 29: 74-83.
79. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999; 159: 1893-900.
80. Collins R, Armitage J, Parish S, Sleigh P, Peto R,; for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
81. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
82. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed March 28, 2014.